Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-156092
Filing Date
2026-04-15
Accepted
2026-04-15 09:00:19
Documents
20
Period of Report
2026-05-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A eq-20260414.htm   iXBRL DEF 14A 1485543
2 GRAPHIC img191336477_0.jpg GRAPHIC 244396
3 GRAPHIC img191336477_1.jpg GRAPHIC 14129
4 GRAPHIC img191336477_2.gif GRAPHIC 91443
5 GRAPHIC img191336477_3.gif GRAPHIC 197519
6 GRAPHIC img191336477_4.gif GRAPHIC 206839
7 GRAPHIC img191336477_5.jpg GRAPHIC 14129
8 GRAPHIC img191336477_6.jpg GRAPHIC 1369867
9 GRAPHIC img191336477_7.jpg GRAPHIC 297931
  Complete submission text file 0001193125-26-156092.txt   8065112

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eq-20260414.xsd EX-101.SCH 29435
25 EXTRACTED XBRL INSTANCE DOCUMENT eq-20260414_htm.xml XML 188634
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037 (858) 412-5302
Equillium, Inc. (Filer) CIK: 0001746466 (see all company filings)

EIN.: 821554746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38692 | Film No.: 26862669
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)